Tirzepatide denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS May Deny Tirzepatide as "Not FDA-Approved"

This denial type is often issued in error or applied to the wrong indication. Tirzepatide has received FDA approval for specific indications — verify the current, complete list of approved indications against the FDA-approved prescribing label before assuming the denial is correct. If your prescriber ordered tirzepatide for an approved indication, this denial is directly contradicted by the public record and is a strong candidate for appeal.

The denial may also reflect a formulary or prior-authorization issue that has been miscoded. Obtain the denial letter in writing and confirm the exact stated reason before proceeding.

## Your Federal Appeal Rights

Under ACA §2719, non-grandfathered individual and group health plans must provide internal and external review. Under ERISA §503, employer-sponsored plans must provide a full-and-fair review. You generally have up to 180 days from receipt of the denial to file an internal appeal, and the external review window typically opens after the internal process is exhausted — the full external-review cycle is generally available for up to approximately 4 months following final internal denial. If your clinical situation is urgent, request an expedited review, which compresses timelines to days rather than months.

## Concrete Appeal Steps

1. Request the denial in writing with the specific coverage determination code and reason. 2. Pull the FDA label for tirzepatide from DailyMed (dailymed.nlm.nih.gov) and confirm the prescribed indication matches an approved indication. 3. Request BCBS's current coverage/medical policy for tirzepatide by name — policies are public and must be provided on request. 4. File the internal appeal within your plan's stated deadline (typically 180 days). 5. If internal appeal fails, request external review through your state insurance commissioner or the federal external-review process.

## Documentation to Gather

• Diagnosis confirmation: chart notes, ICD-10 codes establishing the approved diagnosis
• Prescriber medical-necessity letter: explicitly ties the approved indication to the patient's documented diagnosis
• FDA label excerpt: highlight the relevant approved indication
• Prior treatment history: dates, agents used, and documented outcomes (relevant if step therapy is also a factor)

## Criteria-Mapping Structure

For each requirement stated in the denial or in BCBS's policy, create a two-column table: the requirement on the left, the specific chart evidence satisfying it on the right. For the not-FDA-approved denial specifically, the key mapping is: FDA-approved indication → documented diagnosis in the medical record. If those align, the denial is factually unsupported and should be reversed on internal appeal.